Precision Oncology & Molecular Diagnostics 3 articles

Precision Oncology & Molecular Diagnostics covers cancer testing, biomarkers and analytical systems that use molecular information to classify disease, guide treatment or follow tumor burden. The category spans tissue genomic profiling, liquid biopsy, circulating tumor DNA, molecular residual disease, recurrence assays, screening tests and digital pathology. It keeps the biological marker separate from the assay that measures it and from the company providing the service, preserving distinctions among screening, therapy selection and longitudinal monitoring.

Biotechnology News & Analysis

September 20, 2026, 1:17 AM · 4 mins read

AI agents push into science as safety concerns and funding surge

OpenAI claims a breakthrough on a Millennium Prize problem as billions flow into AI and researchers warn about the risks of runaway systems. Genomics projects show AI’s potential for medicine, even as the industry faces tough questions about safety and oversight.

Biotech Companies & Pipelines

September 19, 2026, 2:30 PM · 4 mins read

Holtec Nuclear delays IPO as Nscale eyes multibillion dollar debut

Holtec Nuclear abruptly postponed its $825 million IPO while Nscale filed for a potential $2 billion offering and Electra Therapeutics suffered a rare biotech IPO drop.

Clinical Trials & Evidence

September 19, 2026, 1:18 AM · 3 mins read

Arovella Therapeutics gets FDA clearance to start first human trial of ALA-101 cell therapy

Arovella Therapeutics has received FDA clearance to begin Phase 1 clinical testing of its allogeneic cell therapy ALA-101 targeting CD19-positive blood cancers.